Anika Therapeutics, Inc. (ANIK) stock
Close on Nov 17, 2026Market cap $171.97MP/E –Yield –
Earnings
Anika Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Anika Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 6, 2026before the open | $30.60M | +10.1% | -$0.02 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 29, 2026before the open | $32.60M | +15.6% | $0.24 | – | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026before the open | $29.60M | +13.0% | -$0.37 | $0.27 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $30.60M | 0.0% | $0.13 | $0.31 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025before the open | $27.80M | -28.4% | – | $0.04 | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025before the open | $28.20M | -32.7% | -$0.33 | -$0.13 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 9, 2025before the open | $26.20M | -35.3% | -$0.28 | -$0.06 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 12, 2025during market hours | $30.60M | -28.8% | -$0.17 | -$0.03 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $38.80M | -6.5% | -$2.03 | -$0.25 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | $41.90M | -5.4% | -$0.01 | $0.17 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024during market hours | $40.50M | +6.9% | -$0.31 | $0.09 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 13, 2024during market hours | $43.00M | +8.6% | -$4.30 | $0.05 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | $41.50M | +3.0% | -$0.45 | $0.00 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | $44.30M | +11.6% | -$0.19 | $0.06 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $37.90M | +3.3% | -$0.71 | -$0.36 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023during market hours | $39.60M | +10.6% | -$0.34 | -$0.21 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022during market hours | $40.30M | +2.0% | -$0.29 | -$0.05 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 3, 2022during market hours | $39.70M | – | -$0.20 | -$0.12 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | $36.70M | – | -$0.20 | -$0.11 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 8, 2022during market hours | $35.80M | – | -$0.40 | -$0.23 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $39.50M | – | $0.04 | $0.05 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 4, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Anika Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Commercial Channel revenue growth | FY2026 | +12% – +18% | +1% – +9% | Raised | Jul 29, 2026 |
| Total Company Revenue | FY2026 | $114.00M – $122.50M | – | New | Apr 29, 2026 |
| Total Company RevenueGAAP | FY2026 | $114.00M – $122.50M | – | New | Feb 26, 2026 |
| Total Company revenue growth | FY2026 | +6% – +10% | +10% – +20% | Lowered | Nov 6, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 15% – 17% | 5% – 10% | Raised | Nov 6, 2026 |
| Adjusted EBITDA as a percent of revenuenon-GAAP | FY2026 | 5% – 10% | – | New | Apr 29, 2026 |
| Adjusted EBITDA marginnon-GAAP | FY2026 | 13% – 17% | – | Raised | Jul 29, 2026 |
| Commercial Channel growth | FY2027 | +10% – +20% | – | New | Jul 30, 2025 |
| Commercial Channel revenue growth | FY2027 | +5% – +15% | – | New | Jul 29, 2026 |
| initial sales for Hyalofast | FY2027 | $3.00M | – | New | Jul 30, 2025 |
Guidance vs results
The last range Anika Therapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $47.00M – $49.50M | $112.80MΣ4Q | Above range |
| FY2025 | Revenue growth | +12% – +18% | -25.69%Σ4Q | Below range |
Guidance history
Every forecast Anika Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 6, 2026 | Adjusted EBITDA margin | FY2026 | 15% – 17% | Raised |
| Nov 6, 2026 | Total Company revenue growth | FY2026 | +6% – +10% | Lowered |
| Jul 29, 2026 | Adjusted EBITDA margin | FY2026 | 13% – 17% | Raised |
| Jul 29, 2026 | Commercial Channel revenue growth | FY2026 | +12% – +18% | Raised |
| Jul 29, 2026 | Total Company Revenue Guidance | FY2026 | +5% – +10% | Lowered |
| Jul 29, 2026 | Commercial Channel revenue growth | FY2027 | +5% – +15% | New |
| Jul 29, 2026 | OEM Channel revenue growth | FY2026 | 0% – +5% | Lowered |
| Apr 29, 2026 | Adjusted EBITDA as a percent of revenue | FY2026 | 5% – 10% | New |
| Apr 29, 2026 | Total Company Revenue growth | FY2026 | +1% – +9% | New |
| Apr 29, 2026 | Commercial Channel growth | FY2026 | +10% – +20% | Raised |
| Apr 29, 2026 | Total Company Revenue | FY2026 | $114.00M – $122.50M | New |
| Apr 29, 2026 | Commercial Channel | FY2026 | $53.00M – $58.00M | Lowered |
| Apr 29, 2026 | OEM Channel | FY2026 | $61.00M – $64.50M | Raised |
| Feb 26, 2026 | Adjusted EBITDA as a percent of revenue | FY2026 | 5% – 10% | New |
| Feb 26, 2026 | Total Company Revenue | FY2026 | $114.00M – $122.50M | New |
| Nov 5, 2025 | Adjusted EBITDA as a percent of revenue | FY2025 | -3% – 3% | New |
| Nov 5, 2025 | Commercial Channel growth | FY2025 | +12% – +18% | New |
| Nov 5, 2025 | OEM Channel growth | FY2025 | -20% – -16% | Lowered |
| Nov 5, 2025 | Commercial Channel | FY2025 | $47.00M – $49.50M | New |
| Nov 5, 2025 | OEM Channel | FY2025 | $62.00M – $65.00M | Raised |
| Jul 30, 2025 | Adjusted EBITDA | FY2025 | -3% – 3% | Reaffirmed |
| Jul 30, 2025 | initial sales for Hyalofast | FY2027 | $3.00M | New |
| Jul 30, 2025 | Commercial Channel growth | FY2025 | +12% – +18% | Raised |
| Jul 30, 2025 | OEM Channel growth | FY2025 | -20% – -16% | Lowered |
| Jul 30, 2025 | Commercial Channel | FY2025 | $47.00M – $49.50M | Lowered |
| Jul 30, 2025 | OEM Channel | FY2025 | $62.00M – $65.00M | Raised |
| Jul 30, 2025 | Commercial Channel growth | FY2026 | +10% – +20% | New |
| Jul 30, 2025 | Commercial Channel growth | FY2027 | +10% – +20% | New |
| May 9, 2025 | Adjusted EBITDA | FY2025 | -3% – 3% | New |
| May 9, 2025 | Commercial Channel revenue growth | FY2025 | +12% – +18% | Raised |
| May 9, 2025 | OEM Channel revenue growth | FY2025 | -20% – -16% | Lowered |
| May 9, 2025 | Commercial Channel revenue | FY2025 | $47.00M – $49.50M | Lowered |
| May 9, 2025 | OEM Channel revenue | FY2025 | $62.00M – $65.00M | Raised |
| Mar 12, 2025 | adjusted EBITDA margin | FY2025 | 8% – 10% | New |
| Mar 12, 2025 | Commercial Channel revenue growth | FY2025 | +12% – +18% | New |
| Mar 12, 2025 | OEM Channel revenue growth | FY2025 | -18% – -12% | Lowered |
| Mar 12, 2025 | Commercial Channel revenue | FY2025 | $47.00M – $49.50M | New |
| Mar 12, 2025 | OEM Channel revenue | FY2025 | $64.00M – $68.50M | Raised |
| Oct 31, 2024 | Adjusted EBITDA | FY2024 | $16.00M – $18.00M | Lowered |
| Oct 31, 2024 | Commercial Channel annual growth | 2026-2027 | +20% – +30% | – |
| Oct 31, 2024 | Commercial Channel growth | FY2024 | +14% – +19% | New |
| Oct 31, 2024 | OEM Channel decline | FY2024 | -10% – -8% | Lowered |
| Oct 31, 2024 | Commercial Channel growth | FY2025 | +12% – +18% | New |
| Oct 31, 2024 | OEM Channel decline | FY2025 | -18% – -12% | Lowered |
| Aug 8, 2024 | adjusted EBITDA | FY2024 | $25.00M – $30.00M | Reaffirmed |
| Aug 8, 2024 | revenue | FY2024 | $168.00M – $173.00M | Reaffirmed |
| May 8, 2024 | adjusted EBITDA | FY2024 | $25.00M – $30.00M | Reaffirmed |
| May 8, 2024 | revenue | FY2024 | $168.00M – $173.00M | New |
| Mar 13, 2024 | adjusted EBITDA | FY2024 | $25.00M – $30.00M | New |
| Mar 13, 2024 | revenue | FY2024 | $168.00M – $173.00M | New |
| Nov 2, 2023 | overall revenue outlook | FY2023 | $164.00M – $166.00M | Raised |
| Aug 8, 2023 | overall revenue outlook | FY2023 | $159.50M – $163.00M | Raised |
| May 9, 2023 | overall revenue | FY2023 | $158.00M – $163.00M | Reaffirmed |
| Mar 6, 2023 | overall revenue | FY2023 | $158.00M – $163.00M | New |
| Aug 3, 2022 | Non-Orthopedic revenue | FY2022 | -20% | Raised |
| Mar 8, 2022 | Non-Orthopedic revenue | FY2022 | -30% | New |
| Nov 4, 2021 | overall revenue | FY2021 | +9% – +11% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Anika Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Update
- Results
See a number that looks wrong?